- In February 2023, Daiichi Sankyo launched an expanded version of edoxaban in Japan targeting high-risk elderly patients with atrial fibrillation.
- In May 2022, Cipla introduced a cost-effective generic version of apixaban in India to increase access for low-income cardiac patients.
- In 2024, Australia’s Therapeutic Goods Administration approved an AI-based decision support tool to optimize personalized anticoagulant therapy in hospitals.
- The report also emphasized the growing importance of real-world evidence, continuous formulation innovation, and regional manufacturing capacity to enhance drug affordability and availability. Increased focus on digital therapeutic integration and patient monitoring tools is shaping the future of anticoagulant care in the Asia-Pacific region.
